Cyclerion Therapeutics, Inc. Share Price & Technical Analysis
CYCN · $3.20 (+0.63%)
Healthcare / Biotechnology
$3.20
+0.63%
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular di…
Price chart
Seasonality
May has 0 positive and 4 negative years (last 5 years shown)
0% return in May, -18% avg return in past 3 year May month.
1% return in 2026, -48% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 17% | 8% | 15% | -39% | 0% | – | – | – | – | – | – | – | 1% |
| 25 | 22% | -32% | -4% | 40% | -20% | 4% | -10% | -7% | -8% | -14% | -16% | -13% | -59% |
| 24 | -14% | 3% | 0% | -15% | -16% | -18% | 71% | -12% | -7% | 16% | -35% | 45% | 19% |
| 23 | -1% | -3% | -28% | -35% | -19% | -11% | -22% | 9% | -3% | -16% | -19% | 43% | -104% |
| 22 | -23% | -21% | 6% | -35% | -15% | -17% | 71% | -6% | 3% | -37% | 73% | -31% | -32% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$13.55M
P/E ratio
—
52W high
$8.48
52W low
$1.03
Volume
29,201
Beta
1.81
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Cyclerion Therapeutics, Inc. share price today?
- Cyclerion Therapeutics, Inc. (CYCN) last traded around $3.20 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CYCN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CYCN. Download the app for real-time alerts.
- How can I analyze Cyclerion Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.